EVIDENCE LIBRARY
Tapentadol Nonmedical-Use Survey Reported Benzodiazepine Co-Use in Selected Respondents
A small anonymous survey found frequent benzodiazepine co-use among respondents answering that item. The percentage was not a population prevalence or an analytically confirmed interaction rate.
A small anonymous survey found frequent benzodiazepine co-use among respondents answering that item. The percentage was not a population prevalence or an analytically confirmed interaction rate.
The surveyed experience
Seventy-eight participants reported nonmedical tapentadol use, with overlapping reports about immediate- and extended-release products. Benzodiazepine co-use was reported by more than half of the respondents in the relevant item subgroups.
Recruitment was web-based, and only a small minority participated in the identifying interactive-chat component.
Read the denominator
The co-use percentages applied to respondents answering particular questions, rather than all prescribed tapentadol users. Product groups and purposes could overlap, so their totals cannot simply be added as separate individuals.
Self-report did not establish exact concurrent timing, doses, product composition, or clinical toxicity. The study helps identify exposure questions and reasons for nonmedical use, but cannot determine the risk of an individual prescription combination or prove that a benzodiazepine caused a reported effect. Actual toxicology and the clinical timeline remain necessary for that attribution.
Source paper
Original analysis of the supplied journal article, identified as PMC9233245.